COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms

Mostrar otras versiones (1)

SARS-CoV-2 infection is required for COVID-19, but many signs and symptoms of COVID-19 differ from common acute viral diseases. SARS-CoV-2 infection is necessary but not sufficient for development of clinical COVID-19 disease. Currently, there are no approved pre- or post-exposure prophylactic COVID...

Descripción completa

Detalles Bibliográficos
Autores principales: Malone, Robert W., Tisdall, Philip, Fremont-Smith, Philip, Liu, Yongfeng, Huang, Xi-Ping, White, Kris M., Miorin, Lisa, Moreno, Elena, Alon, Assaf, Delaforge, Elise, Hennecker, Christopher D., Wang, Guanyu, Pottel, Joshua, Blair, Robert V., Roy, Chad J., Smith, Nora, Hall, Julie M., Tomera, Kevin M, Shapiro, Gideon, Mittermaier, Anthony, Kruse, Andrew C., García-Sastre, Adolfo, Roth, Bryan L., Glasspool-Malone, Jill, Ricke, Darrell O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021898/
https://www.ncbi.nlm.nih.gov/pubmed/33833683
http://dx.doi.org/10.3389/fphar.2021.633680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021898/
https://www.ncbi.nlm.nih.gov/pubmed/33833683
http://dx.doi.org/10.3389/fphar.2021.633680

Ejemplares similares